CGS
data caveat$416MCF+
Cogstate
Diagnostics
Validated digital cognitive testing platform used in Alzheimer's, ADHD and CNS clinical trials globally
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$416M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
171M
Pipeline Assets
2
Latest Insight(1)
15 Apr 2026Insider TradeChange of Director's Interest Notice - MM
6 transactions·-$24833k net sellMyer: bought $24833k, sold $49665k
3M Price
CGS.ASX$2.430+5.7% 3M
Low $2.060High $2.500
Pipeline Assets (2)
Cogstate Brief BatteryCognitive impairment detection (clinical trials)
ApprovedCognigramCognitive assessment (concussion/brain injury)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Cogstate Brief Battery
Capital Raises & Buybacks
7 buybacks
Current shares outstanding: 171M
Buyback
Buyback Detail
2026-03-26on-market
$0.1M
2026-03-26on-market
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
J Formos Med Assoc2026-03· Cogstate Brief Battery
Catalysts (2)· 0 upcoming · 2 past
expand_more2 past catalysts
Confirmedarrow_upwardHigh8 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT03382769
Confirmedarrow_upwardHigh13 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT03382769
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph2Active Not RecruitingEnrollment stale · 2351d
Placebo Oral CapsuleNYX-458
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Mild Cognitive Impairment · Mild Dementia · Parkinson Disease +1 more
RandomizedTriple Blind50 Years – 80 Years
Primary endpoint Change from baseline in physical examination